Note: ASMB nominally has three HBV core inhibitors: i) VBR (f/k/a ABI-H0731), which is in various phase-2 trials using 3-drug regimens, but failed badly in a 2-drug trial with a nuc (#msg-159327881); ii) ABI-H3733 (in phase-1a); and iii) ABI-4334 (preclinical).
A fourth core inhibitor, ABI-H128, was axed due to liver tox (#msg-165734953).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.